Drug Trial Radar · NCT00002582
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,000
Planned (sponsor's estimate)
Start
Jun 1993
Primary completion
Not stated
Study completion Apr 2007
Sponsor
- Lead sponsor
- Institute of Cancer Research, United KingdomAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research Campaign Clinical Trials Centre; Scottish Cancer Therapy Network; Yorkshire Regional Clinical Trials Research Unit
- First posted
- Jul 8, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA breast cancer.
Conditions
- Breast Cancer
Interventions
CMF regimenDrug
cyclophosphamideDrug
doxorubicin hydrochlorideDrug
fluorouracilDrug
goserelin acetateDrug
leuprolide acetateDrug
methotrexateDrug
tamoxifen citrateDrug
oophorectomyProcedure
radiation therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Research Campaign Trials Unit-Birmingham (CRCTU)
Birmingham, England, United Kingdom
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.